MLAB (MLAB) revenue breakdown
By segment, Sterilization and Disinfection Control is the largest at 41% of fiscal 2026 revenue; Biopharmaceutical Development grew fastest, 23% a year over 6 years.
By product, Product is the largest at 82% of fiscal 2026 revenue, growing 12% a year over 9 years.
Revenue by segment
Fiscal years, as MLAB reports them in its 10-K filings; fiscal 2026 total $249M.
| Segments | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sterilization and Disinfection Control | $39M | $43M | $46M | $50M | $53M | $59M | $65M | $75M | $93M | $102M | 41% |
| Calibration Solutions | — | — | — | $52M | $47M | $47M | $45M | $48M | $52M | $54M | 21% |
| Biopharmaceutical Development | — | — | — | $14M | $34M | $46M | $47M | $41M | $49M | $49M | 20% |
| Clinical Genomics | — | — | — | — | — | $33M | $62M | $53M | $47M | $45M | 18% |
| Instruments | $34M | $34M | $36M | — | — | — | — | — | — | — | — |
| Cold Chain Monitoring | $13M | $13M | $14M | — | — | — | — | — | — | — | — |
Revenue by product
Fiscal years, as MLAB reports them in its 10-K filings; fiscal 2026 total $249M.
| Products | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $74M | $74M | $82M | $93M | $107M | $149M | $181M | $177M | $198M | $203M | 82% |
| Service | $20M | $22M | $21M | $24M | $27M | $35M | $39M | $39M | $43M | $46M | 18% |
Revenue by region
Fiscal years, as MLAB reports them in its 10-K filings; fiscal 2026 total $249M.
| Regions | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $53M | $57M | $65M | $66M | $71M | $99M | $117M | $106M | $117M | $117M | 47% |
| Other | — | — | — | — | $56M | $69M | $76M | $85M | $99M | $112M | 45% |
| CHINA | — | — | — | — | $7M | $17M | $26M | $25M | $25M | $20M | 8% |
| Non-US | $41M | $39M | $38M | $51M | — | — | — | — | — | — | — |
Questions
Where does MLAB make its money?
In fiscal 2026, by segment: Sterilization and Disinfection Control $102M, Calibration Solutions $54M, Biopharmaceutical Development $49M, Clinical Genomics $45M.
From MLAB's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.